<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01017952</url>
  </required_header>
  <id_info>
    <org_study_id>102970</org_study_id>
    <nct_id>NCT01017952</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>HZC102970: A 52-week Efficacy and Safety Study to Compare the Effect of Three Dosage Strengths of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on the Annual Rate of Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Purpose of this study is to assess the efficacy and safety of three strengths of the
      FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 25, 2009</start_date>
  <completion_date type="Actual">October 17, 2011</completion_date>
  <primary_completion_date type="Actual">October 1, 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annual Rate of Moderate and Severe COPD Exacerbations Expressed as Least Square Mean</measure>
    <time_frame>From the start of the double blind study medication until Visit 11 (Week 52)/Early Withdrawal</time_frame>
    <description>The annual rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations during the treatment (trt) period (per participant [par.] per year) was assessed. An exacerbation of COPD, is defined as the worsening of two or more major symptoms (dyspnea, sputum volume, sputum purulence [color]) for at least two consecutive days; or the worsening of any one major symptom together with any one of the minor symptoms (sore throat, cold, fever without other cause, increased cough, increased wheeze) for at least two consecutive days. The COPD exacerbation was categorized as mild, moderate and severe by the investigator. Mild: worsening symptoms of COPD that were self-managed by the par. without the use of oral corticosteroids or antibiotics; Moderate: worsening symptoms of COPD that required treatment with oral corticosteroids and/or antibiotics; Severe: worsening symptoms of COPD that required treatment with in-patient hospitalization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to First Occurrence of Moderate or Severe COPD Exacerbation</measure>
    <time_frame>From the start of the double blind study medication until Visit 11 (Week 52)/Early Withdrawal</time_frame>
    <description>Time to first occurrence analyzed by using a Cox proportional hazards model with covariates of treatment, smoking status at screening (stratum), baseline disease severity (pre-dose Day 1 % predicted FEV1) and centre grouping. An exacerbation of COPD is defined as the worsening of two or more major symptoms (dyspnea, sputum volume, sputum purulence [color]) for at least two consecutive days; or the worsening of any one major symptom together with any one of the minor symptoms (sore throat, cold, fever without other cause, increased cough, increased wheeze) for at least two consecutive days. A moderate exacerbation is defined as worsening symptoms of COPD that required treatment with oral corticosteroids and/or antibiotics. A severe exacerbation is defined as worsening symptoms of COPD that required treatment with in-patient hospitalization. The number of participants with a moderate or severe COPD exacerbation while on treatment are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of Exacerbations Requiring Systemic/Oral Corticosteroids Expressed as Least Square Mean</measure>
    <time_frame>From the start of the double blind study medication until Visit 11 (Week 52)/Early Withdrawal</time_frame>
    <description>The annual rate of COPD exacerbations during the treatment period (per participant per year) that required systemic/oral corticosteroids was assessed. An exacerbation of COPD is defined as the worsening of two or more major symptoms (dyspnea, sputum volume, sputum purulence [color]) for at least two consecutive days; or the worsening of any one major symptom together with any one of the minor symptom (sore throat, cold, fever without other cause, increased cough, increased wheeze) for at least two consecutive days. The COPD exacerbation was categorized as mild, moderate, and severe by the investigator. Mild: worsening symptoms of COPD that were self-managed by the participant. Mild exacerbations were not associated with the use of oral corticosteroids or antibiotics. Moderate: worsening symptoms of COPD that required treatment with oral corticosteroids and/or antibiotics. Severe: worsening symptoms of COPD that required treatment with in-patient hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough FEV1 at Week 52 (Visit 11)</measure>
    <time_frame>Baseline to Visit 11 (Week 52)/Early Withdrawal</time_frame>
    <description>Pulmonary function was measured by forced expiratory volume in one second (FEV1). Trough FEV1 was defined as the 24-hour post-dose FEV1 assessment, which was obtained at each visit. Analysis performed using a repeated measures model with covariates of treatment, smoking status at Screening (stratum), baseline (pre-dose Day 1), centre grouping, Week, Week by Baseline, and Week by treatment interactions.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1635</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>FF/GW642444 Inhalation Powder 100/25 mcg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FF/GW642444 Inhalation Powder 50mcg/25mcg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FF/GW642444 Inhalation Powder 200/25 mcg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GW642444 25mcg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Long Acting Beta Agonist(LABA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FF/GW642444 Inhalation Powder</intervention_name>
    <description>Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD</description>
    <arm_group_label>FF/GW642444 Inhalation Powder 200/25 mcg QD</arm_group_label>
    <arm_group_label>FF/GW642444 Inhalation Powder 50mcg/25mcg QD</arm_group_label>
    <arm_group_label>FF/GW642444 Inhalation Powder 100/25 mcg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW642444 Inhalation Powder</intervention_name>
    <description>Long Acting Beta Agonist(LABA) Inhalation Powder</description>
    <arm_group_label>GW642444 25mcg QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type of subject: outpatient

          -  Informed consent: Subjects must give their signed and dated written informed consent
             to participate.

          -  Gender: Male or female subjects A female is eligible to enter and participate in the
             study if she is of: Non-child bearing potential (i.e., physiologically incapable of
             becoming pregnant, including any female who is post-menopausal or surgically sterile).
             Surgically sterile females are defined as those with a documented hysterectomy and/or
             bilateral oophorectomy or tubal ligation. Post-menopausal females are defined as being
             amenorrhoeic for greater than 1 year with an appropriate clinical profile, e.g., age
             appropriate, history of vasomotor symptoms. However in questionable cases, a blood
             sample with FSH &gt; 40MIU/ml and estradiol &lt;40pg/ml (&lt;140 pmol/L) is confirmatory. OR

        Child bearing potential, has a negative pregnancy test at screening, and agrees to one of
        the following acceptable contraceptive methods used consistently and correctly (i.e., in
        accordance with the approved product label and the instructions of the physician for the
        duration of the study - screening to follow-up contact):

          -  Complete abstinence from intercourse from screening until the Follow-Up Phone Contact;
             or

          -  Male partner is sterile (vasectomy with documentation of azoospermia) prior to female
             subject entry into the study, and this male partner is the sole partner for that
             subject; or

          -  Implants of levonorgestral inserted for at least 1 month prior to the study medication
             administration but not beyond the third successive year following insertion; or

          -  Injectable progestogen administered for at least 1 month prior to study medication
             administration and administered until the Follow-Up Phone Contact; or

          -  Oral contraceptive (combined or progestogen only) administered for at least one
             monthly cycle prior to study medication administration; or

          -  Double barrier method: condom or occlusive cap (diaphragm or cervical/vault caps) plus
             spermicidal agent (foam/gel/film/cream/suppository); or

          -  An intrauterine device (IUD), inserted by a qualified physician, with published data
             showing that the highest expected failure rate is less than 1% per year; or

          -  Estrogenic vaginal ring; or

          -  Percutaneous contraceptive patches

               -  Age: ≥40 years of age at Screening (Visit 1)

               -  COPD diagnosis: Subjects with a clinical history of COPD in accordance with the
                  following definition by the American Thoracic Society/European Respiratory
                  Society [Celli, 2004]: COPD is a preventable and treatable disease characterized
                  by airflow limitation that is not fully reversible. The airflow limitation is
                  usually progressive and is associated with an abnormal inflammatory response of
                  the lungs to noxious particles or gases, primarily caused by cigarette smoking.
                  Although COPD affects the lungs, it also produces significant systemic
                  consequences.

               -  Tobacco use: Subjects with a current or prior history of ≥10 pack-years of
                  cigarette smoking at Screening (Visit 1). Former smokers are defined as those who
                  have stopped smoking for at least 6 months prior to Visit 1. Note: Pipe and/or
                  cigar use cannot be used to calculate pack-year history. Number of pack years =
                  (number of cigarettes per day/20) x number of years smoked

               -  Severity of Disease:

          -  Subject with a measured post-albuterol/salbutamol FEV1/FVC ratio of ≤0.70 at Screening
             (Visit 1)

          -  Subjects with a measured post-albuterol/salbutamol FEV1 &lt;70% of predicted normal
             values calculated (via centralized vendor equipment) using NHANES III reference
             equations [Hankinson, 1999] at Screening (Visit 1). Post-bronchodilator spirometry
             will be performed approximately 10-15 minutes after the subject has self-administered
             4 inhalations (i.e., total 400mcg) of albuterol/salbutamol via an MDI with a
             valved-holding chamber. The study provided central spirometry equipment will calculate
             the FEV1/FVC ratio and FEV1 percent predicted values.

               -  History of Exacerbations: A documented history (e.g., medical record
                  verification) of at least one COPD exacerbation in the 12 months prior to Visit 1
                  that required either oral corticosteroids, antibiotics and/or hospitalization.
                  Prior use of antibiotics alone does not qualify as an exacerbation history unless
                  the use was associated with treatment of worsening symptoms of COPD, such as
                  increased dyspnea, sputum volume, or sputum purulence (color). Subject verbal
                  reports are not acceptable.

        Exclusion Criteria:

        Subjects meeting any of the following criteria must not be enrolled in the study:

          -  Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant
             during the study.

          -  Asthma: Subjects with a current diagnosis of asthma. (Subjects with a prior history of
             asthma are eligible if they have a current diagnosis of COPD)

          -  α1-antitrypsin deficiency: Subjects with α1-antitrypsin deficiency as the underlying
             cause of COPD

          -  Other respiratory disorders: Subjects with active tuberculosis, lung cancer,
             bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung
             diseases or other active pulmonary diseases

          -  Lung resection: Subjects with lung volume reduction surgery within the 12 months prior
             to Screening (Visit 1)

          -  Chest X-ray (or CT scan): Subjects with a chest X-ray (or CT scan) that reveals
             evidence of clinically significant abnormalities not believed to be due to the
             presence of COPD. A chest X-ray must be taken at Screening (Visit 1) if a chest X-ray
             or CT scan is not available within 6 months prior to Visit 1. For sites in Germany, if
             a chest X-ray (or CT scan) is not available in the 6 months preceding Screening (Visit
             1), the subject will not be eligible for the study.

          -  Risk Factors for Pneumonia: immune suppression (HIV, Lupus, etc) or other risk for
             pneumonia (e.g. neurological disorders affecting control of the upper airway, such as
             Parkinson's, Myasthenia Gravis, etc).

          -  A moderate and severe COPD exacerbation that has not resolved at least 14 days prior
             to Visit 1 and at least 30 days following the last dose of oral corticosteroids (if
             applicable).

          -  Pneumonia and/or moderate and severe COPD exacerbation at Visit 1 Note: Subjects who
             experience a pneumonia and/or exacerbation at Screening (Visit 1) must be not continue
             in the study, but may be re-screened at a later time provided the pneumonia and/or
             COPD exacerbation has resolved prior to the re-screening visit. At the Re-screening
             Visit, the chest x-ray should confirm resolution of pneumonia. The Re-screening Visit
             must be conducted at least ≥ 14 days following the resolution date of the exacerbation
             and/or pneumonia and at least 30 days following the last dose of oral corticosteroids
             (if applicable).

          -  Other diseases/abnormalities: Subjects with historical or current evidence of
             clinically significant cardiovascular (i.e., pacemaker), neurological, psychiatric,
             renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid
             disease) or haematological abnormalities that are uncontrolled. Significant is defined
             as any disease that, in the opinion of the investigator, would put the safety of the
             subject at risk through participation, or which would affect the efficacy or safety
             analysis if the disease/condition exacerbated during the study.

          -  Peptic Ulcer disease: Subjects with clinically significant peptic ulcer disease that
             is uncontrolled.

          -  Hypertension: Subjects with clinically significant hypertension that is uncontrolled.

          -  Cancer: Subjects with carcinoma that has not been in complete remission for at least 5
             years. Carcinoma in situ of the cervix, squamous cell carcinoma and basal cell
             carcinoma of the skin would not be excluded if the subject has been considered cured
             within 5 years since diagnosis.

          -  Drug/food allergy: Subjects with a history of hypersensitivity to any of the study
             medications (e.g., beta-agonists, corticosteroid) or components of the inhalation
             powder (e.g., lactose, magnesium stearate). In addition, subjects with a history of
             severe milk protein allergy that, in the opinion of the study physician,
             contraindicates the subject's participation will also be excluded.

          -  Drug/alcohol abuse: Subjects with a known or suspected history of alcohol or drug
             abuse within the last 2 years

          -  Medication prior to spirometry: Subjects who are medically unable to withhold their
             albuterol/salbutamol and/or their ipratropium for the 4-hour period required prior to
             spirometry testing at each study visit.

          -  Additional medication: Unable to stop using certain medications such as
             bronchodilators and corticosteroids for the protocol-specified times prior to Visit 1
             (the Investigator will discuss the specific medications)

          -  Oxygen therapy: Subjects receiving treatment with long-term oxygen therapy (LTOT) or
             nocturnal oxygen therapy required for greater than 12 hours a day. Oxygen prn use
             (i.e., ≤12 hours per day) is not exclusionary.

          -  Sleep apnea: Subjects with clinically significant sleep apnea who require use of
             continuous positive airway pressure (CPAP) device or non-invasive positive pressure
             ventilation (NIPPV) device.

          -  Pulmonary rehabilitation: Subjects who have participated in the acute phase of a
             Pulmonary Rehabilitation Program within 4 weeks prior to Screening (Visit 1) or who
             will enter the acute phase of a Pulmonary Rehabilitation Program during the study.
             Subjects who are in the maintenance phase of a Pulmonary Rehabilitation Program are
             not excluded.

          -  Non-compliance: Subjects at risk of non-compliance, or unable to comply with the study
             procedures. Any infirmity, disability, or geographic location that would limit
             compliance for scheduled visits.

          -  Questionable validity of consent: Subjects with a history of psychiatric disease,
             intellectual deficiency, poor motivation or other conditions that will limit the
             validity of informed consent to participate in the study.

          -  Prior use of study medication/other investigational drugs: Subjects who have
             previously been randomized to treatment with GW642444 Inhalation Powder in the
             B2C111045 study, randomized to treatment in the HZC111348 study or have participated
             in the HZC112207, HZC102871, HZC102970, or HZC110946 studies. Subjects who have
             received an investigational drug within 30 days of entry into this study (Screening),
             or within 5 drug half-lives of the investigational drug, whichever is longer.

          -  Affiliation with investigator site: Study investigators, sub-investigators, study
             coordinators, employees of a participating investigator or immediate family members of
             the aforementioned are excluded from participating in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ozark</city>
        <state>Alabama</state>
        <zip>36360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tallassee</city>
        <state>Alabama</state>
        <zip>36078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93726</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Monterey Park</city>
        <state>California</state>
        <zip>91754</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <zip>91950</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Van Nuys</city>
        <state>California</state>
        <zip>91405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Thornton</city>
        <state>Colorado</state>
        <zip>80233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cocoa</city>
        <state>Florida</state>
        <zip>32927</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33183</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Martinez</city>
        <state>Georgia</state>
        <zip>30907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Riverdale</city>
        <state>Georgia</state>
        <zip>30274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Illinois</state>
        <zip>60504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Council Bluffs</city>
        <state>Iowa</state>
        <zip>51503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Olathe</city>
        <state>Kansas</state>
        <zip>66061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <zip>41701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madisonville</city>
        <state>Kentucky</state>
        <zip>42431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>02301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsfield</city>
        <state>Massachusetts</state>
        <zip>01201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cadillac</city>
        <state>Michigan</state>
        <zip>49601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55438</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Papillion</city>
        <state>Nebraska</state>
        <zip>68046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07091</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>North Syracuse</city>
        <state>New York</state>
        <zip>13212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <zip>27215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28625</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Centerville</city>
        <state>Ohio</state>
        <zip>45459</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <zip>29640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Murrells Inlet</city>
        <state>South Carolina</state>
        <zip>29576</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pelzer</city>
        <state>South Carolina</state>
        <zip>29669</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Corsicana</city>
        <state>Texas</state>
        <zip>75110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wichita Falls</city>
        <state>Texas</state>
        <zip>76309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1405BCH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <zip>C1121ABE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mendoza</city>
        <zip>M5500CCG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tucuman</city>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tucumán</city>
        <zip>T4000DGF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kingswood</city>
        <state>New South Wales</state>
        <zip>2747</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Auchenflower</city>
        <state>Queensland</state>
        <zip>4066</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2K 3S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Truro</city>
        <state>Nova Scotia</state>
        <zip>B2N 1L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Grimsby</city>
        <state>Ontario</state>
        <zip>L3M 1P3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8M 1K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5W 6A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <zip>N7T 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8Y 6S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mirabel</city>
        <state>Quebec</state>
        <zip>J7J 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Puente Alto - Santiago</city>
        <state>Región Metro De Santiago</state>
        <zip>8207257</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>Región Metro De Santiago</state>
        <zip>7500691</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Talcahuano</city>
        <zip>4270918</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kobenhavn NV</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kassel</city>
        <state>Hessen</state>
        <zip>34121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marburg</city>
        <state>Hessen</state>
        <zip>35037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wiesbaden</city>
        <state>Hessen</state>
        <zip>65183</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45359</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salerno</city>
        <state>Campania</state>
        <zip>84100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Felice a Cancello Caserta</city>
        <state>Campania</state>
        <zip>81027</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Modena</city>
        <state>Emilia-Romagna</state>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Parma</city>
        <state>Emilia-Romagna</state>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Foggia</city>
        <state>Puglia</state>
        <zip>71100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Palermo</city>
        <state>Sicilia</state>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pisa</city>
        <state>Toscana</state>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Perugia</city>
        <state>Umbria</state>
        <zip>06156</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44600</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zapopan</city>
        <state>Jalisco</state>
        <zip>45040</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Almelo</city>
        <zip>7609 PP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Almere</city>
        <zip>1315 RA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beek</city>
        <zip>6191 JW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Breda</city>
        <zip>4819 EV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Groningen</city>
        <zip>9728 NP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hoorn</city>
        <zip>1624 NP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Horn</city>
        <zip>6085 NM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zutphen</city>
        <zip>7207 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lima 18</city>
        <state>Lima</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Miguel</city>
        <state>Lima</state>
        <zip>Lima 32</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago de Surco</city>
        <state>Lima</state>
        <zip>Lima 33</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Callao</city>
        <zip>Callao 2</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Meyerspark</city>
        <state>Gauteng</state>
        <zip>0184</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Parktown</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Waterkloof Ridge</city>
        <state>Gauteng</state>
        <zip>0181</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bellville</city>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7572</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gatesville</city>
        <zip>7764</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mowbray</city>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roodepoort</city>
        <zip>1724</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Worcester</city>
        <zip>6850</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Alicante</city>
        <zip>03114</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cartagena (Murcia)</city>
        <zip>30202</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cáceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Elda</city>
        <zip>03600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Galdakano</city>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orihuela/Alicante</city>
        <zip>03314</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pama de Mallorca</city>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pozuelo de Alarcón/Madrid</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bankeryd</city>
        <zip>SE-564 31</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Karlskrona</city>
        <zip>SE-371 41</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lidingö</city>
        <zip>SE-181 58</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Åtvidaberg</city>
        <zip>SE-597 26</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bradford on Avon</city>
        <state>Wiltshire</state>
        <zip>BA15 1DQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trowbridge</city>
        <state>Wiltshire</state>
        <zip>BA14 8QA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chertsey, Surrey</city>
        <zip>KT16 0PZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wythenshawe, Manchester</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Sanford L, Lettis S, Crim C, Calverley PM. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013 May;1(3):210-23. doi: 10.1016/S2213-2600(13)70040-7. Epub 2013 Apr 12. Erratum in: Lancet Respir Med. 2013 May;1(3):186.</citation>
    <PMID>24429127</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2009</study_first_submitted>
  <study_first_submitted_qc>November 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2009</study_first_posted>
  <results_first_submitted>May 30, 2013</results_first_submitted>
  <results_first_submitted_qc>August 15, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 19, 2013</results_first_posted>
  <disposition_first_submitted>April 3, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>April 3, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 5, 2012</disposition_first_posted>
  <last_update_submitted>June 12, 2017</last_update_submitted>
  <last_update_submitted_qc>June 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>COPD</keyword>
  <keyword>FEV1</keyword>
  <keyword>Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>102970</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>102970</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>102970</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>102970</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>102970</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>102970</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>102970</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>At Visit (V) 1, eligible participants (par.) entered a 4-week, open-label Run-in Period (RIP) to establish a stable Baseline. At V 2, eligible par. were randomized to a 52-week, double-blind Treatment Period. 2635 par. were screened, 2092 par. entered the RIP, and 1635 par. were randomized, out of which 1633 par. received &gt;=1 study treatment dose.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>FP/SAL 250/50 µg BID</title>
          <description>Participants (Par.) were instructed to take open label Fluticasone Propionate and Salmeterol (FP/SAL) 250/50 microgram (µg) twice daily (BID) from the ACCUHALER/DISKUS, one inhalation each morning and evening with approximately 12 hours between doses. In addition, all par. were provided supplemental albuterol/salbutamol (metered dose inhaler [MDI] and/or nebules) to be used as needed throughout the study.</description>
        </group>
        <group group_id="P2">
          <title>VI 25 µg QD</title>
          <description>Participants received a Vilanterol (VI) 25 µg dry inhalation powder once daily (QD) in the morning from the Dry Powder Inhaler (DPI) for the duration of the 52 weeks. In addition, all participants were provided supplemental albuterol/salbutamol (MDI and/or nebules) to be used as needed throughout the study.</description>
        </group>
        <group group_id="P3">
          <title>FF/VI 50/25 µg QD</title>
          <description>Participants received a Fluticasone Furoate/Vilanterol (FF/VI) 50/25 µg inhalation powder QD in the morning from the NDPI for the duration of the 52 weeks. In addition, all participants were provided supplemental albuterol/salbutamol (MDI and/or nebules) to be used as needed throughout the study.</description>
        </group>
        <group group_id="P4">
          <title>FF/VI 100/25 µg QD</title>
          <description>Participants received a FF/VI 100/25 µg inhalation powder QD in the morning from the NDPI for the duration of the 52 weeks. In addition, all participants were provided supplemental albuterol/salbutamol (MDI and/or nebules) to be used as needed throughout the study.</description>
        </group>
        <group group_id="P5">
          <title>FF/VI 200/25 µg QD</title>
          <description>Participants received a FF/VI 200/25 µg inhalation powder QD in the morning from the NDPI for the duration of the 52 weeks. In addition, all participants were provided supplemental albuterol/salbutamol (MDI and/or nebules) to be used as needed throughout the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>4-week, Open-label Run-In Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2092"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1633"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="459"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did Not Meet Continuation Criteria</title>
              <participants_list>
                <participants group_id="P1" count="356"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Closed/Tterminated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>52-week, Double-blind Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="409"/>
                <participants group_id="P3" count="412"/>
                <participants group_id="P4" count="403"/>
                <participants group_id="P5" count="409"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed the Treatment Period</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="285">Par. completed the treatment period if they attended the last treatment visit (Visit 11).</participants>
                <participants group_id="P3" count="305">Par. completed the treatment period if they attended the last treatment visit (Visit 11).</participants>
                <participants group_id="P4" count="293">Par. completed the treatment period if they attended the last treatment visit (Visit 11).</participants>
                <participants group_id="P5" count="307">Par. completed the treatment period if they attended the last treatment visit (Visit 11).</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="284">Par. completed the study if they completed the treatment period and safety follow-up phone contact.</participants>
                <participants group_id="P3" count="303">Par. completed the study if they completed the treatment period and safety follow-up phone contact.</participants>
                <participants group_id="P4" count="291">Par. completed the study if they completed the treatment period and safety follow-up phone contact.</participants>
                <participants group_id="P5" count="306">Par. completed the study if they completed the treatment period and safety follow-up phone contact.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="125"/>
                <participants group_id="P3" count="109"/>
                <participants group_id="P4" count="112"/>
                <participants group_id="P5" count="103"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="35"/>
                <participants group_id="P5" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="25"/>
                <participants group_id="P5" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met Protocol-Defined Stopping Criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Closed/Terminated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VI 25 µg QD</title>
          <description>Participants received a Vilanterol (VI) 25 µg dry inhalation powder once daily (QD) in the morning from the Dry Powder Inhaler (DPI) for the duration of the 52 weeks. In addition, all participants were provided supplemental albuterol/salbutamol (MDI and/or nebules) to be used as needed throughout the study.</description>
        </group>
        <group group_id="B2">
          <title>FF/VI 50/25 µg QD</title>
          <description>Participants received a Fluticasone Furoate/Vilanterol (FF/VI) 50/25 µg inhalation powder QD in the morning from the NDPI for the duration of the 52 weeks. In addition, all participants were provided supplemental albuterol/salbutamol (MDI and/or nebules) to be used as needed throughout the study.</description>
        </group>
        <group group_id="B3">
          <title>FF/VI 100/25 µg QD</title>
          <description>Participants received a FF/VI 100/25 µg inhalation powder QD in the morning from the NDPI for the duration of the 52 weeks. In addition, all participants were provided supplemental albuterol/salbutamol (MDI and/or nebules) to be used as needed throughout the study.</description>
        </group>
        <group group_id="B4">
          <title>FF/VI 200/25 µg QD</title>
          <description>Participants received a FF/VI 200/25 µg inhalation powder QD in the morning from the NDPI for the duration of the 52 weeks. In addition, all participants were provided supplemental albuterol/salbutamol (MDI and/or nebules) to be used as needed throughout the study.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="409"/>
            <count group_id="B2" value="412"/>
            <count group_id="B3" value="403"/>
            <count group_id="B4" value="409"/>
            <count group_id="B5" value="1633"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.6" spread="9.29"/>
                    <measurement group_id="B2" value="63.7" spread="9.56"/>
                    <measurement group_id="B3" value="64.0" spread="9.28"/>
                    <measurement group_id="B4" value="63.5" spread="8.84"/>
                    <measurement group_id="B5" value="63.7" spread="9.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="174"/>
                    <measurement group_id="B2" value="181"/>
                    <measurement group_id="B3" value="181"/>
                    <measurement group_id="B4" value="191"/>
                    <measurement group_id="B5" value="727"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="235"/>
                    <measurement group_id="B2" value="231"/>
                    <measurement group_id="B3" value="222"/>
                    <measurement group_id="B4" value="218"/>
                    <measurement group_id="B5" value="906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="360"/>
                    <measurement group_id="B2" value="359"/>
                    <measurement group_id="B3" value="353"/>
                    <measurement group_id="B4" value="359"/>
                    <measurement group_id="B5" value="1431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American/ African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American/African Heritage &amp; White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native &amp; White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian &amp; White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Annual Rate of Moderate and Severe COPD Exacerbations Expressed as Least Square Mean</title>
        <description>The annual rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations during the treatment (trt) period (per participant [par.] per year) was assessed. An exacerbation of COPD, is defined as the worsening of two or more major symptoms (dyspnea, sputum volume, sputum purulence [color]) for at least two consecutive days; or the worsening of any one major symptom together with any one of the minor symptoms (sore throat, cold, fever without other cause, increased cough, increased wheeze) for at least two consecutive days. The COPD exacerbation was categorized as mild, moderate and severe by the investigator. Mild: worsening symptoms of COPD that were self-managed by the par. without the use of oral corticosteroids or antibiotics; Moderate: worsening symptoms of COPD that required treatment with oral corticosteroids and/or antibiotics; Severe: worsening symptoms of COPD that required treatment with in-patient hospitalization.</description>
        <time_frame>From the start of the double blind study medication until Visit 11 (Week 52)/Early Withdrawal</time_frame>
        <population>Intent-to-Treat (ITT) Population: all par. randomized who received at least 1 dose of study drug and with available data for analysis. Analysis used a negative binomial regression model with covariates of trt, smoking status at Screening, Baseline pre-dose Day 1 % predicted FEV1 and region and with logarithm of time on trt as an offset variable.</population>
        <group_list>
          <group group_id="O1">
            <title>VI 25 µg QD</title>
            <description>Participants received a Vilanterol (VI) 25 µg dry inhalation powder once daily (QD) in the morning from the Dry Powder Inhaler (DPI) for the duration of the 52 weeks. In addition, all participants were provided supplemental albuterol/salbutamol (MDI and/or nebules) to be used as needed throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>FF/VI 50/25 µg QD</title>
            <description>Participants received a Fluticasone Furoate/Vilanterol (FF/VI) 50/25 µg inhalation powder QD in the morning from the DPI for the duration of the 52 weeks. In addition, all participants were provided supplemental albuterol/salbutamol (MDI and/or nebules) to be used as needed throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>FF/VI 100/25 µg QD</title>
            <description>Participants received a FF/VI 100/25 µg inhalation powder QD in the morning from the DPI for the duration of the 52 weeks. In addition, all participants were provided supplemental albuterol/salbutamol (MDI and/or nebules) to be used as needed throughout the study.</description>
          </group>
          <group group_id="O4">
            <title>FF/VI 200/25 µg QD</title>
            <description>Participants received a FF/VI 200/25 µg inhalation powder QD in the morning from the DPI for the duration of the 52 weeks. In addition, all participants were provided supplemental albuterol/salbutamol (MDI and/or nebules) to be used as needed throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of Moderate and Severe COPD Exacerbations Expressed as Least Square Mean</title>
          <description>The annual rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations during the treatment (trt) period (per participant [par.] per year) was assessed. An exacerbation of COPD, is defined as the worsening of two or more major symptoms (dyspnea, sputum volume, sputum purulence [color]) for at least two consecutive days; or the worsening of any one major symptom together with any one of the minor symptoms (sore throat, cold, fever without other cause, increased cough, increased wheeze) for at least two consecutive days. The COPD exacerbation was categorized as mild, moderate and severe by the investigator. Mild: worsening symptoms of COPD that were self-managed by the par. without the use of oral corticosteroids or antibiotics; Moderate: worsening symptoms of COPD that required treatment with oral corticosteroids and/or antibiotics; Severe: worsening symptoms of COPD that required treatment with in-patient hospitalization.</description>
          <population>Intent-to-Treat (ITT) Population: all par. randomized who received at least 1 dose of study drug and with available data for analysis. Analysis used a negative binomial regression model with covariates of trt, smoking status at Screening, Baseline pre-dose Day 1 % predicted FEV1 and region and with logarithm of time on trt as an offset variable.</population>
          <units>Exacerbations per participant per year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="409"/>
                <count group_id="O2" value="412"/>
                <count group_id="O3" value="403"/>
                <count group_id="O4" value="409"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" lower_limit="0.99" upper_limit="1.32"/>
                    <measurement group_id="O2" value="0.92" lower_limit="0.79" upper_limit="1.07"/>
                    <measurement group_id="O3" value="0.90" lower_limit="0.77" upper_limit="1.05"/>
                    <measurement group_id="O4" value="0.79" lower_limit="0.67" upper_limit="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.040</p_value>
            <method>Generalized Linear Model</method>
            <method_desc>Assuming Negative Binomial distribution with logarithm of time on treatment as an offset variable.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.024</p_value>
            <method>Generalized Linear Model</method>
            <method_desc>Assuming Negative Binomial distribution with logarithm of time on treatment as an offset variable.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Generalized Linear Model</method>
            <method_desc>Assuming Negative Binomial distribution with logarithm of time on treatment as an offset variable.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Occurrence of Moderate or Severe COPD Exacerbation</title>
        <description>Time to first occurrence analyzed by using a Cox proportional hazards model with covariates of treatment, smoking status at screening (stratum), baseline disease severity (pre-dose Day 1 % predicted FEV1) and centre grouping. An exacerbation of COPD is defined as the worsening of two or more major symptoms (dyspnea, sputum volume, sputum purulence [color]) for at least two consecutive days; or the worsening of any one major symptom together with any one of the minor symptoms (sore throat, cold, fever without other cause, increased cough, increased wheeze) for at least two consecutive days. A moderate exacerbation is defined as worsening symptoms of COPD that required treatment with oral corticosteroids and/or antibiotics. A severe exacerbation is defined as worsening symptoms of COPD that required treatment with in-patient hospitalization. The number of participants with a moderate or severe COPD exacerbation while on treatment are presented.</description>
        <time_frame>From the start of the double blind study medication until Visit 11 (Week 52)/Early Withdrawal</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>VI 25 µg QD</title>
            <description>Participants received a Vilanterol (VI) 25 µg dry inhalation powder once daily (QD) in the morning from the Dry Powder Inhaler (DPI) for the duration of the 52 weeks. In addition, all participants were provided supplemental albuterol/salbutamol (MDI and/or nebules) to be used as needed throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>FF/VI 50/25 µg QD</title>
            <description>Participants received a Fluticasone Furoate/Vilanterol (FF/VI) 50/25 µg inhalation powder QD in the morning from the DPI for the duration of the 52 weeks. In addition, all participants were provided supplemental albuterol/salbutamol (MDI and/or nebules) to be used as needed throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>FF/VI 100/25 µg QD</title>
            <description>Participants received a FF/VI 100/25 µg inhalation powder QD in the morning from the DPI for the duration of the 52 weeks. In addition, all participants were provided supplemental albuterol/salbutamol (MDI and/or nebules) to be used as needed throughout the study.</description>
          </group>
          <group group_id="O4">
            <title>FF/VI 200/25 µg QD</title>
            <description>Participants received a FF/VI 200/25 µg inhalation powder QD in the morning from the DPI for the duration of the 52 weeks. In addition, all participants were provided supplemental albuterol/salbutamol (MDI and/or nebules) to be used as needed throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Occurrence of Moderate or Severe COPD Exacerbation</title>
          <description>Time to first occurrence analyzed by using a Cox proportional hazards model with covariates of treatment, smoking status at screening (stratum), baseline disease severity (pre-dose Day 1 % predicted FEV1) and centre grouping. An exacerbation of COPD is defined as the worsening of two or more major symptoms (dyspnea, sputum volume, sputum purulence [color]) for at least two consecutive days; or the worsening of any one major symptom together with any one of the minor symptoms (sore throat, cold, fever without other cause, increased cough, increased wheeze) for at least two consecutive days. A moderate exacerbation is defined as worsening symptoms of COPD that required treatment with oral corticosteroids and/or antibiotics. A severe exacerbation is defined as worsening symptoms of COPD that required treatment with in-patient hospitalization. The number of participants with a moderate or severe COPD exacerbation while on treatment are presented.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="409"/>
                <count group_id="O2" value="412"/>
                <count group_id="O3" value="403"/>
                <count group_id="O4" value="409"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197"/>
                    <measurement group_id="O2" value="198"/>
                    <measurement group_id="O3" value="177"/>
                    <measurement group_id="O4" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.177</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.036</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>0.82</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Rate of Exacerbations Requiring Systemic/Oral Corticosteroids Expressed as Least Square Mean</title>
        <description>The annual rate of COPD exacerbations during the treatment period (per participant per year) that required systemic/oral corticosteroids was assessed. An exacerbation of COPD is defined as the worsening of two or more major symptoms (dyspnea, sputum volume, sputum purulence [color]) for at least two consecutive days; or the worsening of any one major symptom together with any one of the minor symptom (sore throat, cold, fever without other cause, increased cough, increased wheeze) for at least two consecutive days. The COPD exacerbation was categorized as mild, moderate, and severe by the investigator. Mild: worsening symptoms of COPD that were self-managed by the participant. Mild exacerbations were not associated with the use of oral corticosteroids or antibiotics. Moderate: worsening symptoms of COPD that required treatment with oral corticosteroids and/or antibiotics. Severe: worsening symptoms of COPD that required treatment with in-patient hospitalization.</description>
        <time_frame>From the start of the double blind study medication until Visit 11 (Week 52)/Early Withdrawal</time_frame>
        <population>Intent-to-Treat (ITT) Population: all par. randomized who received at least 1 dose of study drug and with available data for analysis. Analysis used a negative binomial regression model with covariates of trt, smoking status at Screening, Baseline pre-dose Day 1 % predicted FEV1 and region and with logarithm of time on trt as an offset variable.</population>
        <group_list>
          <group group_id="O1">
            <title>VI 25 µg QD</title>
            <description>Participants received a Vilanterol (VI) 25 µg dry inhalation powder once daily (QD) in the morning from the Dry Powder Inhaler (DPI) for the duration of the 52 weeks. In addition, all participants were provided supplemental albuterol/salbutamol (MDI and/or nebules) to be used as needed throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>FF/VI 50/25 µg QD</title>
            <description>Participants received a Fluticasone Furoate/Vilanterol (FF/VI) 50/25 µg inhalation powder QD in the morning from the DPI for the duration of the 52 weeks. In addition, all participants were provided supplemental albuterol/salbutamol (MDI and/or nebules) to be used as needed throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>FF/VI 100/25 µg QD</title>
            <description>Participants received a FF/VI 100/25 µg inhalation powder QD in the morning from the DPI for the duration of the 52 weeks. In addition, all participants were provided supplemental albuterol/salbutamol (MDI and/or nebules) to be used as needed throughout the study.</description>
          </group>
          <group group_id="O4">
            <title>FF/VI 200/25 µg QD</title>
            <description>Participants received a FF/VI 200/25 µg inhalation powder QD in the morning from the DPI for the duration of the 52 weeks. In addition, all participants were provided supplemental albuterol/salbutamol (MDI and/or nebules) to be used as needed throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of Exacerbations Requiring Systemic/Oral Corticosteroids Expressed as Least Square Mean</title>
          <description>The annual rate of COPD exacerbations during the treatment period (per participant per year) that required systemic/oral corticosteroids was assessed. An exacerbation of COPD is defined as the worsening of two or more major symptoms (dyspnea, sputum volume, sputum purulence [color]) for at least two consecutive days; or the worsening of any one major symptom together with any one of the minor symptom (sore throat, cold, fever without other cause, increased cough, increased wheeze) for at least two consecutive days. The COPD exacerbation was categorized as mild, moderate, and severe by the investigator. Mild: worsening symptoms of COPD that were self-managed by the participant. Mild exacerbations were not associated with the use of oral corticosteroids or antibiotics. Moderate: worsening symptoms of COPD that required treatment with oral corticosteroids and/or antibiotics. Severe: worsening symptoms of COPD that required treatment with in-patient hospitalization.</description>
          <population>Intent-to-Treat (ITT) Population: all par. randomized who received at least 1 dose of study drug and with available data for analysis. Analysis used a negative binomial regression model with covariates of trt, smoking status at Screening, Baseline pre-dose Day 1 % predicted FEV1 and region and with logarithm of time on trt as an offset variable.</population>
          <units>Exacerbations per participant per year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="409"/>
                <count group_id="O2" value="412"/>
                <count group_id="O3" value="403"/>
                <count group_id="O4" value="409"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" lower_limit="0.72" upper_limit="1.03"/>
                    <measurement group_id="O2" value="0.72" lower_limit="0.60" upper_limit="0.86"/>
                    <measurement group_id="O3" value="0.66" lower_limit="0.55" upper_limit="0.80"/>
                    <measurement group_id="O4" value="0.56" lower_limit="0.46" upper_limit="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.154</p_value>
            <method>Generalized Linear Model</method>
            <method_desc>Assuming Negative Binomial distribution with logarithm of time on treatment as an offset variable.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.041</p_value>
            <method>Generalized Linear Model</method>
            <method_desc>Assuming Negative Binomial distribution with logarithm of time on treatment as an offset variable</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Generalized Linear Model</method>
            <method_desc>Assuming Negative Binomial distribution with logarithm of time on treatment as an offset variable</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough FEV1 at Week 52 (Visit 11)</title>
        <description>Pulmonary function was measured by forced expiratory volume in one second (FEV1). Trough FEV1 was defined as the 24-hour post-dose FEV1 assessment, which was obtained at each visit. Analysis performed using a repeated measures model with covariates of treatment, smoking status at Screening (stratum), baseline (pre-dose Day 1), centre grouping, Week, Week by Baseline, and Week by treatment interactions.</description>
        <time_frame>Baseline to Visit 11 (Week 52)/Early Withdrawal</time_frame>
        <population>ITT Population. Number of participants presented represent those with data available at the time point being presented, however all participants in the ITT population without missing covariate information and with at least one post Baseline measurement are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>VI 25 µg QD</title>
            <description>Participants received a Vilanterol (VI) 25 µg dry inhalation powder once daily (QD) in the morning from the Dry Powder Inhaler (DPI) for the duration of the 52 weeks. In addition, all participants were provided supplemental albuterol/salbutamol (MDI and/or nebules) to be used as needed throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>FF/VI 50/25 µg QD</title>
            <description>Participants received a Fluticasone Furoate/Vilanterol (FF/VI) 50/25 µg inhalation powder QD in the morning from the DPI for the duration of the 52 weeks. In addition, all participants were provided supplemental albuterol/salbutamol (MDI and/or nebules) to be used as needed throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>FF/VI 100/25 µg QD</title>
            <description>Participants received a FF/VI 100/25 µg inhalation powder QD in the morning from the DPI for the duration of the 52 weeks. In addition, all participants were provided supplemental albuterol/salbutamol (MDI and/or nebules) to be used as needed throughout the study.</description>
          </group>
          <group group_id="O4">
            <title>FF/VI 200/25 µg QD</title>
            <description>Participants received a FF/VI 200/25 µg inhalation powder QD in the morning from the DPI for the duration of the 52 weeks. In addition, all participants were provided supplemental albuterol/salbutamol (MDI and/or nebules) to be used as needed throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough FEV1 at Week 52 (Visit 11)</title>
          <description>Pulmonary function was measured by forced expiratory volume in one second (FEV1). Trough FEV1 was defined as the 24-hour post-dose FEV1 assessment, which was obtained at each visit. Analysis performed using a repeated measures model with covariates of treatment, smoking status at Screening (stratum), baseline (pre-dose Day 1), centre grouping, Week, Week by Baseline, and Week by treatment interactions.</description>
          <population>ITT Population. Number of participants presented represent those with data available at the time point being presented, however all participants in the ITT population without missing covariate information and with at least one post Baseline measurement are included in the analysis.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="276"/>
                <count group_id="O2" value="304"/>
                <count group_id="O3" value="287"/>
                <count group_id="O4" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.019" spread="0.0116"/>
                    <measurement group_id="O2" value="0.015" spread="0.0113"/>
                    <measurement group_id="O3" value="0.005" spread="0.0115"/>
                    <measurement group_id="O4" value="0.006" spread="0.0113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.034</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.034</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.003</ci_lower_limit>
            <ci_upper_limit>0.066</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.143</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.024</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.008</ci_lower_limit>
            <ci_upper_limit>0.056</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.115</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.026</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.006</ci_lower_limit>
            <ci_upper_limit>0.057</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events (SAEs) and non-serious AEs will be collected from Baseline to the end of the treatment period (up to 52 weeks).</time_frame>
      <desc>SAEs and non-serious adverse events are reported for members of the Intent-to-Treat Population, comprised of all randomized participants who received at least one dose of study medication during the treatment period.</desc>
      <group_list>
        <group group_id="E1">
          <title>VI 25 µg QD</title>
          <description>Participants received a Vilanterol (VI) 25 µg dry inhalation powder once daily (QD) in the morning from the Dry Powder Inhaler (DPI) for the duration of the 52 weeks. In addition, all participants were provided supplemental albuterol/salbutamol (MDI and/or nebules) to be used as needed throughout the study.</description>
        </group>
        <group group_id="E2">
          <title>FF/VI 50/25 µg QD</title>
          <description>Participants received a Fluticasone Furoate/Vilanterol (FF/VI) 50/25 µg inhalation powder QD in the morning from the DPI for the duration of the 52 weeks. In addition, all participants were provided supplemental albuterol/salbutamol (MDI and/or nebules) to be used as needed throughout the study.</description>
        </group>
        <group group_id="E3">
          <title>FF/VI 100/25 µg QD</title>
          <description>Participants received a FF/VI 100/25 µg inhalation powder QD in the morning from the DPI for the duration of the 52 weeks. In addition, all participants were provided supplemental albuterol/salbutamol (MDI and/or nebules) to be used as needed throughout the study.</description>
        </group>
        <group group_id="E4">
          <title>FF/VI 200/25 µg QD</title>
          <description>Participants received a FF/VI 200/25 µg inhalation powder QD in the morning from the DPI for the duration of the 52 weeks. In addition, all participants were provided supplemental albuterol/salbutamol (MDI and/or nebules) to be used as needed throughout the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="61" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Megacolon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Oesophageal achalasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways diseas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung squamous cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Bone neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Bronchial neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Metastases to gastrointestinal tract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Neoplasm recurrence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Neuroendocrine tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pelvic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Urinary bladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pulmonary bulla</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Labile blood pressure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="211" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="229" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="239" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="249" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="82" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Oropharyngeal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="403"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

